logo
  Join        Login             Stock Quote

Complete Genomics (GNOM) Mulling Strategic Alternatives, Including Possible Sale

 June 05, 2012 07:23 AM


(By Balachander) Complete Genomics Inc. (NASDAQ:GNOM) is looking at strategic alternatives, including a possible a sale or equity investment and the company announced a restructuring program that included jobs cuts.

The Mountain View, California-based developer of DNA sequencing platform for human genome sequencing said it intends to focus on clinical sequencing and the restructuring plan positions it to capture this emerging opportunity.

During the quarter ending June 30, roughly 55 jobs will be cut in Mountain View, California, and other U.S. locations due to a delay in expanding capacity, the company said. The company will maintain its current monthly capacity of about 1,000 genomes at 40x coverage or 500 genomes at 80x coverage and it expects delay capacity expansion beyond those numbers until demand for clinical-grade genomes supports expansion.

[Related -Illumina (ILMN) Says Court Agrees To Review Patent Decision]

For the first quarter ended March 31, the company posted a wider loss as revenue dropped and expenses increased. Its net loss widened to $20.2 million from $12.5 million, while revenue plunged 43 percent to $3.9 million.

As of March 31, 2012, the company's backlog was around 5,700 genomes, including about 1,000 genomes booked in the first quarter, representing an aggregate revenue potential of roughly $27 million.

The company has engaged Jefferies & Company Inc. to act as its financial advisor to assist in its review of strategic alternatives.

The stock, which has been trading in the 52-week range between $1.57 and $18.55, ended Monday's regular trading at $2.04.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.